IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders.
Industry: Health Care
Latest Trade: $16.85 0.00 (0.0%)
First Day Return: +42.5%
Return from IPO: -0.9%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 03/19/2021 |
Offer Price | $17.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 7.5 |
Deal Size ($mm) | $128 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 04/08/2021 |
Offer Price | $17.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 7.5 |
Deal Size ($mm) | $128 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
BofA Securities |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | Basel, Switzerland |
Founded | 2019 |
Employees | n/a |
Website vectivbio.com |